Mott MacDonald has been appointed by AstraZeneca UK to design a major new four-storey research and development facility at the company’s site at Alderley Park, Cheshire, UK.
Mott MacDonald will be providing structural, civil and architectural design, as well as overall design coordination and construction support for the project as part of an alliance framework.
The building will house several research departments including a pre-clinical imaging facility, and will replace and expand existing facilities on site which are being demolished as part of the project. Demolition material will be crushed on site and re-used to create the new buildings.
Chris Oakes, Mott MacDonald’s project manager explained, “This is an important facility for AstraZeneca, and the design brief was necessarily complex to accommodate the pharmaceutical capabilities. As a result Mott MacDonald was required to have an understanding of the company’s complex inter-departmental relationships and specialist operations. The design will be modelled using three-dimensional design software complete with clash detection٭ and walk-through capability to provide detailed visualisations of the completed building. This approach will be used to carry out design co-ordination between the other design consultants and equipment vendors.”
He added, “The site is located in the centre of a very busy operational research and development facility, so from a construction viewpoint minimal disruption to existing operations and services will be a key requirement of the project.”